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Introduction
The discovery of new chemical entities for medical research, 
diagnostics or basic research is being obtained by the screen-
ing of large chemical libraries. These libraries are composed of 
related/unrelated molecules and constitute a potential source 
of new leads for the medical field. A r elatively new type of 
chemical libraries includes the aptamers. Aptamers are short 
single-stranded nucletodic molecules (ssDNA or ssARN) with 
the ability to fold in a stable three-dimensional structure that 
allows them to interact sterically and through electrostatic 
interactions with a target molecule. In general, they are 15–
80 nucleotides long. Aptamers are identified from synthetic 
ssDNA or ssRNA libraries through a process termed SELEX 
(Systematic Evolution of Ligands by  EXponential enrichment).1 
They have been selected to bind a plethora of targets includ-
ing small molecules, peptides, proteins, and cells.2 So far, the 
accumulated data on aptamer functionality have demonstrated 
that antibodies are no longer the only entities that may be 
developed to bind to targets with high affinity and specificity.
Although aptamer technology is not robust yet, contin-
ued efforts are being made toward its consolidation given 
its numerous advantages over current technologies.3 The 
application of aptamer technology for the detection of 
myelin basic protein (MBP) has not fully been exploited and 
a MBP-specific aptamer could lead to a potential therapeu-
tic drug for multiple sclerosis (MS) or a novel reagent for 
myelin detection.
MBP is the most widely studied myelin protein in MS and 
the second most abundant myelin protein after the proteolipid 
protein4 that constitutes the myelin sheath, which is neces-
sary for the normal activity of the vertebrate nervous system. 
MBP has various isoforms generated by alternative splic-
ing, which include the classical 18.5 and 21.5 kDa isoforms. 
These proteins are highly basic; however, various post-trans-
lational modifications can generate different charge isomers.5 
MBP is considered to be an intrinsically unstructured protein 
and its conformation is defined by its environment or upon 
association with a ligand.6 While the presence of disordered 
sequences makes it difficult to solve the protein crystal struc-
ture, this characteristic and the basicity of the protein render 
it very attractive for aptamer-targeting.
Much evidence suggests that MBP may be an autoanti-
gen candidate in MS.7 In particular, MBP-specific T cells have 
been isolated from MS patients and healthy  individuals.8–14 
Hence, MBP seems to play an important role in MS pro-
gression and could therefore be an interesting drug target. 
Published data suggest that in MS patients, autoantibod-
ies recognize MBP and recruit inflammatory cells to focal 
areas, thereby targeting the central nervous system myelin 
components and affecting its stability. Moreover, T cells in 
MS patients are able to recognize MBP peptides exposed 
at the surface of antigen-presenting cells, which triggers an 
immune response against MBP.
We hypothesized that a molecule able to protect MBP from 
autoantibodies may be a good neuroprotective agent. Addi-
tionally, life science researchers and clinicians may benefit 
from the identification of an aptamer able to detect MBP in 
tissue sections. This would indeed provide the possibility of 
a one-step staining of myelin under physiological conditions 
or permit the detection of myelin-rich regions using different 
types of dyes.
The present study reports the selection process of an 
aptamer specific for MBP. We demonstrate its ability to detect 
MBP in different in vitro assays and mouse brain tissue sec-
tions as well as its capacity to compete with a specific anti-MBP 
antibody. We also discuss the potential use of this molecule as 
a therapeutic agent, diagnostic agent and research tool.
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Aptamer ligands for myelin basic protein (MBP) were obtained using the systematic evolution of ligand by exponential 
enrichment (SELEX) method. Two clones were isolated from a pool of oligonucleotides and tested for MBP targeting. Using 
purified MBP, we demonstrated the binding activity of the aptamers and we also showed the affinity of MBP for oligonucleotides 
of specific length. Moreover, one selected aptamer competitively inhibited the binding of an MBP-specific antibody to MBP 
and the aptamer was found more sensitive than a commercial antibody. In addition, we showed the ability of the aptamer 
to detect myelin-rich regions in paraffin-embedded mouse brain tissue. Therefore, the MBP-binding activity of the selected 
oligonucleotide may prove useful as a tool for life science and medical research for myelin detection and might be a good lead 
for testing it in autoimmune diseases such as multiple sclerosis.
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Single-stranded DNA molecules exhibiting high affinity for 
mouse MBP were obtained by an in vitro aptamer selection pro-
cedure, named SELEX. Our initial ssDNA library was designed 
to contain a randomized sequence region of 35 nucleotides, 
and be flanked by fixed primer sites. High biases in composition 
of the nucleotide library may lead to an unsuccessful SELEX, 
such that equal representation of four nucleotides is preferred. 
To test for the nucleotide composition, our initial pool of aptam-
ers was cloned out and 20 individual clones were sequenced, 
resulting in a composition of 27% A, 29.4% C, 19.7% G, and 
23.4% T. Several variables were modified during the succes-
sive SELEX rounds in order to increase the stringency of the 
selection (Table 1). The SELEX was started with a library of 
~3 × 1014 distinct ssDNA molecules. Aptamers obtained at the 
15th cycle (MBP C15) were analyzed using a radio isotope-
free dot-blot assay  (Figure 1a), which has become a common 
technique for protein detection, and may be performed by most 
research laboratories due to its simplicity and speed. Figure 1a 
shows the MBP-binding activity of the selected pool of aptam-
ers compared to the activity of another pool of aptamers that 
had been selected to an unrelated protein. Whereas the bind-
ing activity of the unspecific pool of aptamers is comparable to 
a control without aptamers, MBP C15 showed a higher binding 
activity suggesting that the pool of aptamers was enriched for 
molecules that have affinity for MBP. This aptamer pool was 
therefore cloned out and 15 individual clones were sequenced. 
Sequences were clustered into groups based on their nucleo-
tide content, which revealed two prominent families with highly 
conserved sequences, represented by the clones MBPcl3 and 
MBPcl9 (Figure 1b). Interestingly, the length of the randomized 
region was shortened in both sequences. Indeed, while the 
original ssDNA library was designed to contain ssDNA mole-
cules with a 35-nucleotide long randomized region, the aptamer 
obtained after 15 rounds of SELEX displayed a 26-nucleotide 
long randomized region. 5′ biotinylated versions of MBPcl9, 
MBPcl3, and of the unselected random library were generated 
by solid-phase synthesis for further studies in enzyme-linked 
immunosorbent assay (ELISA)-like assays. These assays fol-
lowed the basic principles of an ELISA with the difference that 
the first antibody is replaced by an aptamer conjugated to a 
reporter for detection with a secondary horseradish peroxidase 
(HRP)-conjugated antibody. Our ELISA-like assay also differs 
from the enzyme-linked oligonucleotide assay,15 which only 
makes use of oligonucleotides for detection.
The MBP-binding activity of MBPcl3 and MBPcl9 was com-
pared and no statistical difference was found (Figure 2a). Inter-
estingly, the unselected aptamer pool also showed a strong 
interaction with immobilized MBP suggesting that the protein 
binds to nucleic acids irrespective of their sequence due to 
its highly positive net charge at physiological pH. However, it 
is also possible that the binding activity resides in part within 
the fixed reverse primer-annealing region of the aptamer. 
Sequence analysis of both aptamer clones revealed a highly 
conserved nucleotide sequences between the randomized 
region and the constant reverse primer-annealing region of 
the aptamers. To determine if the binding activity of MBPcl3 
Table 1 Protein and aptamer quantity, washing stringency and incubation 











1 0.500 1.5 No 120 3
2 0.111 0.333 Yes 120 3
3 0.091 0.183 Yes 120 3
4 0.084 0.169 Yes 120 3
5 0.084 0.084 Yes 120 3
6 0.159 0.159 No 120 4
7 0.196 0.098 Yes 120 4
8 0.171 0.085 No 120 4
9 0.247 0.061 Yes 120 4
10 0.171 0.042 No 120 5
11 0.183 0.045 Yes 60 5
12 0.135 0.033 Yes 60 5
13 0.077 0.015 No 30 5
14 0.089 0.017 No 30 5
15 0.097 0.019 No 30 5
SELEX, systematic evolution of ligand by exponential enrichment.
Figure 1 Dot-blot analysis of the selected library after 15 rounds of systematic evolution of ligand by exponential enrichment 
(SELEX). (a) 1 µg of pure myelin basic protein (MBP) was spotted onto nitrocellulose membranes and incubated with equal nmol of 
different biotinylated aptamers. MBP C15 is the selected library against MBP; “unspecific” is another pool of aptamers selected against an 
unrelated target; “none” is without aptamers. Bound aptamers were detected with an alkaline phosphatase-conjugated anti-biotin antibody 
and developed with NBT/BCIP substrates. Relative intensities were measured with the ImageJ software. (b) Sequence alignment of the 
two most representative clones found in the enriched library selected for its affinity for MBP. After the 15th round of selection, the aptamer 
pool was cloned out and sequenced. MBPcl3 had the highest frequency among all nucleotide sequences followed by MBPcl9. Sequences 
corresponding to the constant primer regions are underlined. Letters in bold show differences between the two clones.
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was sequence specific, a scrambled version of MBPcl3 was 
generated by randomizing its nucleotide sequence and its 
MBP binding activity was assessed.  Figure 2b clearly shows 
that the integrity of MBPcl3 sequence is necessary for its 
binding to the target molecule.
Structural analysis
To further investigate whether aptamer sequence can be min-
imized, structural analysis of MBPcl9 and MBPcl3 was per-
formed with Mfold16 to predict the most likely single-stranded 
DNA secondary structures (Figure 3a–c). MBPcl9 structure 
displayed an inverted L-shape (Figure 3a) with two long 
stems, each followed by a pair of loops, and contained sev-
eral unpaired 3′ terminal nucleotides. On the other hand, two 
optimal structures were shown for MBPcl3 with comparable 
free energies. One of these structures showed an inverted 
L-shaped figure, similar to MBPcl9 (Figure 3b). The second 
structure (Figure 3c) contained a higher number of unpaired 
nucleotides. The difference between MBPcl3 and MBPcl9 
resided in the nucleotides at position 25 and 26 correspond-
ing to CG and TA, respectively. While the TA nucleotides are 
part of the long stem 5 in MBPcl9, the CG pair in MBPcl3 is 
either included in the loop E or among the unpaired nucleo-
tides, suggesting that these two nucleotides allow MBPcl3 to 
adopt different conformational structures. This result allowed 
to define distinct domains that contain stems and loops such 
that shorter versions of the MBP-specific aptamers were gen-
erated by solid-phase synthesis and tested for their affinity 
for MBP (Figure 3d). Aptamer domain AF comprised stem 5 
with loops A and F, domain BC included stem 8 and loops B 
and C, while domain AE contained stem 7 with loops A and 
E  (Figure 3a–c). Interestingly, all three shorter versions of 
aptamer MBPcl3 and MBPcl9 were found to lose the MBP-
binding activity, suggesting that a full length version of MBPcl3 
and MBPcl9 is necessary for their MBP-binding activity.
MBP aptamer specificity
In order to analyze whether the MBPcl3 aptamer is able to 
detect MBP in a complex mixture of proteins, 1 or 0.5 µg 
of MBP was immobilized onto wells of a microtiter plate 
and a cleared Hela cells lysate was added to the wells. 
Wells were then coated with bovine serum albumin (BSA) 
to block the remaining free  surface. In consequence, if 
there was a high unspecific binding activity of MBPcl3, a 
higher absorbance should be expected in wells containing 
0.5 µg of MBP due to a higher surface availability for the 
binding of soluble Hela cell proteins. The absorbance mea-
sured in wells containing 0.5 µg of MBP was much lower 
than in wells originally coated with 1 µg of MBP, reflecting a 
reduced protein–aptamer interaction in the former, thereby 
indicating that MBPcl3  specifically detected MBP in a mix-
ture of proteins (Figure 4).
MBP-binding activity of an anti-MBP antibody compared 
to MBPcl3
MBPcl3-binding activity was also compared with a commer-
cial polyclonal anti-MBP antibody. For this purpose, equal 
molar concentrations of MBPcl3 and anti-MBP antibody 
were incubated with 0.5 µg of MBP (Figure 5a). Interest-
ingly, MBPcl3 was found to bind MBP almost fivefolds more 
effectively than the antibody. In addition, MBPcl3 was also 
compared to the anti-MBP antibody in a complex mixture of 
proteins as described before (Figure 5b). For MBP detec-
tion, 7 pmol of either MBPcl3 or anti-MBP antibody was 
used. Figure 5b shows that MBPcl3 was able to detect MBP, 
while the anti-MBP antibody did not. MS is a disease where 
autoimmune antibodies play a key role. The recognition of 
MBP by autoantibodies induces the recruitment of lympho-
cytes to MBP sites and could participate in the degradation 
of the myelin protein. In order to test whether MBPcl3 could 
inhibit the activity of an MBP-specific antibody, a competi-
tion assay was performed (Figure 5c). MBPcl3 and the anti-
MBP antibody were incubated at  different times or together 
in Microlon ELISA microplates that contained previously 
immobilized MBP. Figure 5c shows that the presence of 
MBPcl3 blocked the binding of the antibody to MBP and 
that this effect was greater when MBPcl3 and the anti-MBP 
antibody were incubated together.
Figure 2 Myelin basic protein (MBP)-binding activity of MBPcl3 aptamer using an ELISA-like assay. 0.5 µg of pure MBP was incubated 
in a microtiter plate with equal nmol of an unselected aptamer library (Lib35), MBPcl3 or MBPcl9 (a) or with a scrambled MBPcl3 aptamer 
whose entire nucleotide sequence was randomly rearranged (b). Bound aptamers were detected with horseradish peroxidase (HRP)-
conjugated avidin and developed with 3,3’,5,5’-tetramethylbenzidine (TMB) substrate (dark gray). Wells without MBP were used as controls 
(light gray). Experiments were performed in triplicate. The asterisk indicates a significant difference in comparison with MBPcl3 (P < 0.05, 































MBP Binds to Oligonucleotides
Rozenblum et al.
4
MBP peptide binding of MBPcl3 aptamer
The recognition by T-cell receptors of antigenic peptides 
exposed on the surface of antigen presenting cells is con-
sidered an important step in MS progression. Thus, an MBP 
peptide comprising residues 90–106 (MBP90106) was synthe-
sized and the MBP90106-binding activity of MBPcl3 was tested 
in an ELISA-like assay. Interestingly, MBPcl3 was able to bind 
MBP90106 as well as the unselected aptamer pool (Figure 6).
Histochemistry
In order to test the ability of MBPcl3 to detect MBP in tis-
sues, we used mouse brain sections for histochemical 
reaction. MBPcl3 was able to recognize myelin-rich regions 
in the mouse brain (Figure 7). Brain areas known to con-
tain neural fibers including the corpus callosum, cere-
bral penduncle, thalamic radiation, fasciculus retroflexus, 
and premammilary nucleus (Figure 7b) were reactive to 
MBPcl3. The pattern of MBP detection through MBPcl3 
was  comparable to that observed with anti-MBP antibody 
(Figure 7a).
Discussion
SELEX is a proven methodology to obtain active nucleic 
acids with the ability to bind specific targets (for reviews, see 
refs. 2,17). Essentially SELEX consists in repeated  binding 
tests, selections and amplifications of aptamers from an ini-
tial library until enrichment of specific molecules is obtained. 
Aptamers are being tested for different purposes such as 
protein purification18 or for protein-function regulation in an 
antagonistic or agonistic manner.19–21
In this study, we obtained specific aptamers against pure 
MBP from mice containing mainly the 18.5 kDa isoform. 
Whereas the aptamer library was designed to contain a 
randomized region of 35 nucleotides, two selected clones, 
namely MBPcl3 and MBPcl9, showed a shorter random-
ized region of 26 nucleotides that mediated the MBP-binding 
activity in nitrocellulose membranes and in ELISA microtiter 
plates. Interestingly, the unselected library of aptamers was 
found to also bind MBP suggesting a natural affinity of MBP 
for nucleic acids. Nevertheless, the MBP-binding activity of a 
Figure 3 Aptamer conformations and their binding activities. Upper panel shows schematic representations of secondary structures of 
MBPcl3 and MBPcl9 as predicted by the mfold program. (a) is the predicted most favorable structure for MBPcl9; (b) and (c) are two different 
possible conformations for MBPcl3 with similar free energies. The myelin basic protein (MBP)-binding activity of three different MBPcl3 
domains was determined by an enzyme-linked immunosorbent assay (ELISA)-like assay (d). 0.5 µg of pure MBP was immobilized onto wells 
of a microtiter plate and incubated with MBPcl3 or equal nmol of MBPcl3 or MBPcl9 truncated products. Truncation was performed to retain a 
stem-loop structure. MBPcl9 AF includes Stem 5, Loop A and F; MBPcl3 BC includes stem 4 and 8 and loops B and C; MBPcl3 AE includes 
stem 7 with loops A and E. Experiments were performed in duplicate. The asterisks indicate a significant difference in comparison with MBPcl3 
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scrambled version of MBPcl3 aptamer was not as good as 
the unmodified MBPcl3, showing that binding was sequence-
specific and not simply due to physicochemical properties 
of the protein. MBP binding of the unselected aptamer pool 
might, therefore, arise from the primer-annealing region 
present at both the aptamer and the library. The analysis of 
MBPcl3 and cl9 randomized region showed (sequence) simi-
larity to the reverse primer-annealing region that might drive 
MBP binding. On the other hand, MBP contains a strong pos-
itive net charge at physiological pH, and its nucleic acid bind-
ing activity could be driven mainly by electrostatic interaction. 
Indeed, it is well known that MBP binds negatively charged 
molecules such as the polar head of acidic lipids22,23 and 
fluorescently labeled triphosphate nucleotides.24 Even more, 
Smith et al.25 have proposed the presence of a nontraditional 
nuclear localization signal on MBP that allows to translocate 
the protein to the nucleus. Hence, our results add new insight 
on the ability of MBP to bind nucleic acids in vitro and it is 
likely that binding activity might occur in vivo.
The secondary structure of MBPcl3 and MBPcl9 aptamers 
was predicted with mFold16 to rationally detect possible active 
domains. Shorter versions of both aptamers were synthesized. 
MBPcl9 AF and MBPcl3 BE domains contained the forward 
primer-priming region, while MBPcl3 BC contained part of the 
reverse primer-priming region. However, none of them was 
able to equal the activity of the full-length MBPcl3 suggesting 
that the whole nucleotide sequence is required for the binding 
activity of the aptamer. Similarly, chemokine platelet factor 4 
(PF4) is another highly positive charged-protein with the abil-
ity to bind many negatively charged polyanions and recently 
nucleic acids were added to the list.26 Interestingly, PF4 was 
able to bind RNA and DNA of different length, sequence and 
structural configurations that regulated its activity. Jaax et al. 
showed that longer constructs (45mer) are more potent regula-
tors than shorter ones (10-21mer). However, many of the con-
clusions observed by Jaax et al. were based on an experimental 
assay that was not indicative of the presence of nucleic acids 
bound to PF4 but rather to the ability of PF4 to bind platelets 
in the presence of nucleic acids. In addition, an aptamer that 
binds to myelin, named 3064, has been recently raised using 
a suspension of crude murine myelin.27 It was shown that not 
only aptamer 3064 had the ability to bind to myelin but also the 
aptamer control. In agreement with this, our results also sug-
gest an intrinsic ability of MBP to bind nucleic acids, although 
it is not fully understood whether MBP is able to bind any kind 
of oligonucleotide or its binding is length-, sequence-, and/or 
structure-related. Nastasijevic et al.27 shed a little more light 
in this issue showing the inability of a 40mer oligodeoxythy-
midylate molecule to bind myelin. Thus, further effort should 
be directed toward identifying the affinity constant of MBPcl3 
aptamer and understanding the effect nucleic acids length, 
sequence and structural configuration on the binding to myelin.
MBPcl3 was also able to detect MBP in a complex mixture 
of proteins in a concentration-dependent manner. In addition, 
MBPcl3 binding activity was compared to that of an anti-
MBP polyclonal antibody. Using equivalent amounts of both 
the aptamer and the antibody, we observed a higher binding 
activity with MBPcl3. Moreover, while 7 pmol of aptamer was 
sufficient to detect MBP in a complex mixture of proteins, the 
same amount of anti-MBP antibody was not, suggesting that 
MBPcl3 has a higher affinity for MBP than the antibody.
MBPcl3 was also used to detect myelin-rich areas in 
mouse brain tissue sections. Currently, there are only a few 
methods for myelin staining in tissue sections, which include 
Luxor Fast Blue described by Kluver and Barrera in 1953,28 
Black Gold II (BKII) commercialized by Merck and the classi-
cal antibody-mediated immune reaction. Luxor Fast Blue and 
BKII are the cheapest approaches but they are not only time-
consuming methodologies but also involve processing the 
tissue in nonphysiological conditions. Antibodies constitute 
the most expensive alternative although they allow research-
ers to work under physiological conditions, with the possibility 
of selecting a variety of dye-conjugated antibodies and stain 
tissues in a fewer steps. On the contrary, MBPcl3 results 
from a relatively cheap and easy approach to synthesize 
molecules with multiple advantages over antibodies, Luxor 
Fast Blue and BKII methods. MBPcl3 may be synthesized by 
solid-phase and is more amenable to modifications during 
its manufacture such that virtually any type of dye, enzyme, 
or marker may be added during this process. Furthermore, 
staining can be performed under physiological conditions 
and the number of staining steps may be reduced to only 
one (e.g., MBPcl3 conjugated to an alkaline phosphatase or 
horseradish peroxidase). The finding that MBPcl3 is able to 
identify MBP in tissue sections suggests that it may become 
a great research tool for histochemical staining of the central 
nervous system and opens up a promising technical output 
of aptamers for molecule detection and cell localization.
Finally, MBPcl3 could be also a great therapeutic lead and it 
would be very interesting to try in the near future its activity in 
different animal models of MS. MS is an inflammatory disease 
that affects the central nervous system and leads to substan-
tial disabilities through deficits of sensation and impaired motor, 
Figure 4 Myelin basic protein (MBP)-binding activity of the 
MBPcl3 aptamer in a complex mixture of proteins. A cleared 
lysate of Hela cells was immobilized onto a microtiter plate 
containing 1 µg, 0.5 µg, or nothing of pure MBP. Wells were then 
coated with 3% BSA such that wells with lesser amount of MBP 
contained a higher amount of either the Hela cell lysate or the 
BSA protein. Therefore, the observed difference between the two 
treatments may only be explained by the difference in the amount 
of MBP. Experiments were performed in triplicate. The asterisk 
indicates a significant difference when compared to MBPcl3 1 µg 
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autonomic, and neurocognitive functions. At present, no cure 
exists for MS and current treatments aim to arrest or slow the 
progression of the disease and alleviate the symptoms. MS is 
currently considered to be a CD4+ Th1-mediated autoimmune 
disease.7,29 This assumption is based on the cellular composi-
tion of brain and cerebrospinal fluid-infiltrating cells and data 
obtained from the experimental autoimmune encephalomy-
elitis model.30 Experimental autoimmune encephalomyelitis is 
induced in susceptible rats and mice by the injection of myelin 
components, promoting a CD4+-mediated autoimmune disease 
that shares similarities with MS.7,30 Despite clear indications of 
CD4+ Th1 cells key role in the disease, its etiology remains 
unknown. Slowing down, halting the disease progression or 
reversing its effects remains an unmet objective for patients 
with MS. MBP constitutes one of the major components of 
the myelin sheath31 and is found throughout the whole myelin 
sheath.32 Previous works confirmed that many MS patients carry 
MBP autoantibodies and suggest that these antibodies may be 
responsible for the loss of myelin in neuronal axons.7,33–35 More-
over, it has been proposed that the antigenic epitope of MBP 
was located between residues 61 and 110.36 Hence, targeting 
the MBP protein may result in an immune-protective therapy by 
blocking either the interaction between autoantibodies and the 
endogenous MBP or by blocking the activation immunoreactive 
T-cells that recognize MBP peptides displayed on the surface 
of antigen-presenting cells. Indeed, this study showed that the 
MBPcl3 aptamer inhibited the MBP-binding activity of an MBP-
specific antibody and that MBPcl3 was also able to interact with 
an MBP peptide comprising residues 90–106. Thus, it would 
be very interesting to analyze in the future whether MBPcl3 
aptamer is able to block MBP- mediated T-cell activation.
In summary, this is the first report to show an aptamer 
capable to detect MBP in tissue sections and demon-
strate the potential of MBPcl3 as a medical research tool. 
Figure 5 The myelin basic protein (MBP)-binding activity of an antibody compared to MBPcl3. (a) Equal nmol of MBPcl3 and of the 
antibody were incubated with the MBP that was first immobilized on a microtiter plate. Wells without MBP were used as controls (light gray). (b) A 
cleared lysate of Hela cells was immobilized on a microtiter plate containing 1 or 0.5 µg of pure MBP. Wells were then blocked with 3% BSA and 
after washing 7 pmol of aptamer or antibody was added. (c) 0.5 µg of pure MBP was immobilized onto a microtiter plate and incubated with 0.028 
nmol of MBPcl3, 0.010 nmol of anti-MBP antibody or with both at different times. Columns from left to right: (1) MBP incubated with anti-MBP 
antibody, washed and then with the MBPcl3 aptamer. (2) MBP incubated with the antibody only. (3) MBP incubated with MBPcl3, washed and 
then with anti-MBP antibody. (4) anti-MBP and MBPcl3 aptamer incubated together. For (a), (b), and (c), fraction of bound antibody was detected 
with an horseradish peroxidase (HRP)-conjugated anti-rabbit antibody and developed with 3,3’,5,5’-tetramethylbenzidine (TMB) substrate, while 
for (a) and (b), fraction of bound aptamer was detected with an HRP-conjugated avidin. Experiments were performed in triplicate. The asterisks 
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This work also opens the possibility for the development of 
novel aptamer-based therapeutic approaches to pursue bet-
ter drugs in diseases such as MS. However, more efforts 
should be directed towards understanding the nature of the 
MBP-oligonucleotides interaction.
Materials and methods
Materials. Mouse myelin basic protein, Bovine Serum Albu-
min fraction V, alkaline phosphatase-conjugated monoclonal 
anti-biotin, and anti-MBP polyclonal antibodies were pur-
chased from Sigma Aldrich (St Luis, MO). Yeast tRNA was 
purchased from Biodynamics (BA, Argentina). Taq Poly-
merase and dideoxynucleotides were obtained from Fer-
mentas (Vilnius, Lithuania). Alkaline phosphatase substrate 
NBT/BCIP and HRP substrate 3,3’,5,5’-tetramethylbenzidine 
were purchased from Promega (Madison, WI). HRP-conju-
gated avidin was purchased from Pierce (Rockford, IL). High 
binding Microlon ELISA plates were obtained from Greiner 
Bio-One (Monroe, NC). All oligonucleotides were synthe-
sized by Integrated DNA Technologies (Coralville, IA). Nitro-
cellulose Hybond ECL membranes were obtained from GE 
Healthcare (Piscataway, NJ). Salmon sperm DNA and Sybr 
Gold were purchased from Life Technologies (Gran Island, 
NY). All other reagents and chemicals were of the highest 
purity available and were obtained from commercial sources.
SELEX. The ssDNA library was designed to con-
tain a randomized sequence region of 35 nucleotides, 
and to be flanked by constant primer annealing regions 
(5′-GCGTCGATTGCCATGGGTTG(N)35 cacgcagtgagctcccc 
tggacc-3′). A biased molar mixture (30% A, 30% C, 20% G, and 
Figure 7 Detection of myelin-rich regions in mouse brain sections through immunostaining with anti-myelin basic protein (MBP) 
polyclonal antibody (a) and oligo-stained with the MBPcl3 aptamer (b–f). (c–f) are higher magnifications of squared areas in (b). (d) 














Figure 6 Detection of a myelin basic protein (MBP) peptide 
with MBPcl3 aptamer. Two micrograms of pure MBP peptide 
were incubated in a microtiter plate with equal nmol of an 
unselected aptamer library (Lib35) or MBPcl3. Bound aptamers 
were detected with HRP-conjugated avidin and developed with 
3,3’,5,5’-tetramethylbenzidine (TMB) substrate (dark gray). Wells 
without MBP peptide were used as controls (light gray). Experiments 
were performed in triplicate. One asterisk indicates a significant 
difference in comparison with MBPcl3 and two asterisks indicates a 
significant difference in comparison with Lib35 (P < 0.05, Student’s 
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20% T) of the four phosphoramidites was used to compensate 
for their incorporation efficiencies and to generate a truly ran-
domized region. The first round of selection was initiated with 
0.5 nmol (~3 × 1014 molecules) of ssDNA. Prior to selections, 
ssDNAs were diluted in selection buffer (SB; 20 mmol/l Tris-HCl 
pH 7.6, 150 mmol/l NaCl, 5 mmol/l MgCl2), denatured at 95 °C 
for 5 minutes and cooled on ice for another 5 minutes. Affinity 
selections were done as follows: MBP was immobilized onto 
a nitrocellulose membrane disc and blocked in blocking buffer 
(SB containing 2% BSA) for 60 minutes. After several washes 
with SB, MBP was incubated with the ssDNA library at 37 °C for 
a fixed period of time (Table 1). Counter-selections of aptamers 
were performed by incubating the ssDNA library with nitrocel-
lulose membrane discs that had been blocked with blocking 
buffer for 60 minutes at SELEX cycle 2, 3, 4, 5, 7, 9, 11, and 12. 
Molar ratio of MBP to aptamers, washing stringency, and incu-
bation time were modified over the SELEX cycles (Table 1). 
After washing with SB, the aptamers bound to MBP were eluted 
in distilled water by heating the complex at 95 °C for 10 min-
utes. Asymmetric polymerase chain reaction (PCR) was per-
formed with eluted aptamers in 100 µl reaction mix containing 
2 µmol/l forward primer 5′-GCGTCGATTGCCATGGGTTG-3′; 
0.02 µmol/l reverse primer 5′- GGTCCAGGGGAGCTCACT-
GCGTG-3′; 200 µmol/l of each dNTP; 10 mmol/l Tris-HCl (pH 
8.8 at 25 °C), 50 mmol/l KCl, 0.08% (v/v) Nonidet P40 and 0.8 
mmol/l MgCl
2. Thermal cycling consisted of one cycle at 95 °C 
for 10 minutes and multiple cycles at 95 °C for 30 seconds, 58 
°C for 40 seconds, and 72 °C for 40 seconds. The number of 
PCR cycles was estimated empirically at each round of SELEX 
to avoid the amplification of PCR products of incorrect size by 
analyzing an aliquot of the PCR product on a 3% agarose gel 
electrophoresis every 10 PCR cycles containing sybr gold for 
visualization. Following PCR amplification, the ssDNA library 
was ethanol-precipitated and pelleted by centrifugation. The 
pellet was dried under vacuum and resuspended in distilled 
water for the next cycle of selection.
Cloning and sequencing. Aptamers from the 15th round 
of selection were asymmetrically PCR-amplified, purified, 
and an aliquot was used as a template for a standard PCR. 
dsDNA PCR products were cloned using the pGEM-T Easy 
kit (Promega) and individual clones of transformed bacteria 
were screened for the presence of aptamers with the cor-
rect size. Plasmid DNA extracted from single colonies was 
sequenced at the Instituto Nacional de Tecnología Agro-
pecuaria (Castelar, Argentina). Sequence alignments were 
performed with CLUSTAL W.
Dot blotting. Biotinylated aptamers were generated by asym-
metric PCR with a 5′ biotinylated forward primer and purified. 
Aptamers were heated at 95 °C for 5 minutes and then cooled 
on ice for another 5 minutes. Pure MBP protein was spotted 
onto 0.45 µm pore-size nitrocellulose membranes and air-
dried in a BioRad biodot system. Membranes were blocked 
with blocking buffer or Tris buffer saline (TBS; 20 mmol/l Tris-
HCl pH 7.5, 500 mmol/l NaCl) with 2% BSA for 1 hour at room 
temperature. Membranes were then washed three times with 
SB or TBS and incubated with 0.014 nmol of aptamers in 
SB or TBS containing 0.1 mg/ml of yeast tRNA for 2 hours at 
37 °C. Then, membranes were washed three times with SB 
or TBS and incubated for 1 hour at room temperature with 
alkaline phosphatase -conjugated anti-biotin monoclonal 
antibody in SB or TBS containing 2% BSA. Membranes were 
washed three times and biotinylated aptamers were detected 
with NBT/BCIP alkaline phosphatase substrate.
ELISA-like binding assays. A high binding Microlon microtiter 
plate was coated overnight with MBP or a MBP peptide com-
prising residues 90–106 (Anaspec, cat. 60977. CA) in 100 µl of 
0.05 mol/l sodium carbonate pH 9.6. Wells were washed three 
times with phosphate buffer saline containing Tween 20 (PBS-
T; 1 mmol/l KH
2PO4, 10 mmol/l Na2HPO4, 137 mmol/l NaCl, 2.7 
mmol/l KCl, 0.05% Tween 20) and blocked with PBS-T contain-
ing 3% BSA for 1 hour. Then, wells were washed three times 
with SB and incubated with aptamers in SB supplemented with 
0.1 mg/ml of yeast tRNA or salmon sperm DNA. Before addi-
tion to the wells, aptamers were heated at 95 °C for 5 minutes 
and cooled on ice for another 5 minutes. Wells containing MBP 
and incubated without aptamers and wells without MBP and 
incubated with aptamers were used as internal controls. Wells 
were washed three times with SB and incubated with HRP-
avidin in SB containing 2% BSA for 1 hour. Then, wells were 
washed three times with SB and 3,3’,5,5’-tetramethybenzidine 
was used as HRP substrate. Absorbance was measured at 
450 nm in a Biotek µQuant microplate spectrophotometer.
Activity of MBPcl3 in cell lysates. Three 10 cm Ø cell culture 
plates of Hela cells (ATCC CCL-2.1) cultured to confluence 
were washed twice with PBS and lysed in 400 µl of radio 
immunoprecipitation assay buffer (50 mmol/l Tris-HCl pH 7.4, 
150 mmol/l NaCl, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% sodium dodecyl sulfate, 0.2 mmol/l phenylmethylsulfonyl 
fluoride, 10 nmol/l leupeptin, and 10 pg/ml aprotinin). Lysates 
were centrifuged at 15,000× g in a table centrifuge at 4 °C for 
15 minutes. High binding Microlon microtiter plates were pre-
pared with MBP as described above and 75 µl of cell lysate 
was added to each well containing different amounts of MBP 
for 1 hour. Wells without MBP were used as internal controls. 
After three washes with PBS-T, wells containing MBP pro-
tein and cell lysates were blocked with PBS-T containing 3% 
BSA for 1 hour. Addition of aptamers and detection followed 
as described earlier (see ELISA-like binding assays) with the 
difference that  aptamers were synthesized with nucleotide 
analogues containing phosphorothioate interlinkages.
Histochemistry. Brains from adult BALB/c mice were fixed 
in cold 4% paraformaldehyde (PFA) in 0.1 mol/l phosphate 
buffer (pH 7.4) for 72 hours, dehydrated through a graded 
series of ethanol, and embedded in paraffin. Paraffin-
embedded tissues were sectioned at 5 µm thickness. Histo-
chemical identification of myelin was performed as follows: 
tissue sections were deparaffinized in xylene, rehydrated 
through a decreasing series (100, 95, 70, and 50%) of etha-
nol, washed in distilled water for 5 minutes, and stored in 
SB 1X until further use. For myelin detection with aptamer 
MBPcl3, tissue sections were incubated in PBS containing 
4% PFA and 0.3% Triton for 1 minute, washed in SB 1X, and 
blocked in SB 1X containing 2% BSA for 30 minutes. Tissue 
sections were then washed and incubated with 5 mmol/l of 
5′ biotinylated MBPcl3 aptamer for 2 hours at 37 °C in SB 
www.moleculartherapy.org/mtna
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1X containing 4 µg of salmon sperm gDNA. Sections were 
then washed, incubated with an anti-biotin alkaline phospha-
tase-conjugated antibody for 1 hour in SB 1X containing 2% 
BSA and alkaline phosphatase activity was revealed using 
SIGMA’s Magenta kit. Examination was performed with a 
Nikon Eclipse E200 upright microscope. For myelin detection 
with a commercial anti-MBP antibody, tissue sections were 
incubated in PBS containing 4% PFA and 0.3% Triton for 1 
minute, washed in PBS, and treated with 0.3% H2O2 in water 
to quench endogenous peroxidase activity. Sections were 
then washed in PBS, blocked in PBS containing 2% BSA 
for 30 minutes, washed again in PBS and incubated with a 
rabbit anti-MBP antibody (1 × 102 dilution) in PBS contain-
ing 1% BSA for 1 hour at room temperature. Sections were 
then washed and incubated with an anti-rabbit IgG HRP-
conjugated antibody for 1 hour in PBS containing 1% BSA 
and staining was performed with the Vectastatin Elite ABC kit 
rabbit (Rabbit IgG) from Vector Laboratories (CA). Examina-
tion was performed with a Nikon Eclipse E200 upright micro-
scope or a Nikon T1 confocal microscope equipped with 
transmission light and a Nikon Digital Sight DS-Fi1 camera.
Statistical Analysis. Results from at least two independent 
experiments in high binding Microlon microtiter plates were 
analyzed and the P values were calculated with the Student’s 
t-test. Differences were considered statistically significant 
when P < 0.05.
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